Key Takeaways:
(Bloomberg) -- Faruqi & Faruqi, LLP has issued a reminder to investors in REGENXBIO Inc. (NASDAQ: RGNX) of the fast-approaching April 14, 2026, deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the company.
"If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson," the firm stated in its notice.
The class action lawsuit pertains to investors who suffered losses in REGENXBIO during the specified period. The New York-based law firm, which specializes in national securities litigation, is investigating potential claims that the company may have violated federal securities laws.
This legal action introduces considerable uncertainty for REGENXBIO, carrying potential for substantial financial damages and heightened legal costs. The allegations could erode investor confidence, casting doubt on the company's disclosures and transparency during the nearly four-year class period.
The reminder of the April 14 deadline serves as a critical notice for investors who believe their losses are connected to the alleged misconduct. Seeking the role of lead plaintiff allows an investor to have a more active role in directing the litigation.
This article is for informational purposes only and does not constitute investment advice.
